Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival

BJU International

Volumn 102, Issue 11, 2008, Pages 1694-1699

  Gardner, Erin R ^b   Ahlers, Christoph M ^a   Shukla, Suneet ^a   Sissung, Tristan M ^a   Ockers, Sandra B ^a   Price, Douglas K ^a   Hamada, Akinobu ^a   Robey, Robert W ^a   Steinberg, Seth M ^a   Ambudkar, Suresh V ^a   Dahut, William L ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Diet; Mutations; Prostate cancer; Risk; Survival; Transport

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; BREAST CANCER RESISTANCE PROTEIN; TESTOSTERONE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DIET; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 56649114649     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07913.x     Document Type: Article

References (33)

1. Ito N, Hasegawa R, Sano M et al. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 1991 12 : 1503 6
2. Shirai T, Sano M, Tamano S et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 1997 57 : 195 8
3. Bogen KT, Keating GA. U.S. dietary exposures to heterocyclic amines. J Expo Anal Environ Epidemiol 2001 11 : 155 68
4. Cross AJ, Peters U, Kirsh VA et al. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 2005 65 : 11779 84
5. Sinha R, Kulldorff M, Chow WH, Denobile J, Rothman N. Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001 10 : 559 62
6. Sinha R, Peters U, Cross AJ et al. Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res 2005 65 : 8034 41
7. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002 52 : 213 35
8. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006 86 : 1179 236
9. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004 279 : 19781 9
10. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005 6 : 115 38
11. Fetsch PA, Abati A, Litman T et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 2006 235 : 84 92
12. Pascal LE, Oudes AJ, Petersen TW et al. Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol 2007 7 : 6
13. Obligacion R, Murray M, Ramzan I. Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl 2006 27 : 138 50
14. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006 112 : 457 73
15. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007 26 : 39 57
16. de Jong FA, Marsh S, Mathijssen RH et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004 10 : 5889 94
17. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2004 109 : 238 46
18. Morisaki K, Robey RW, Ozvegy-Laczka C et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005 56 : 161 72
19. Imai Y, Nakane M, Kage K et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002 1 : 611 6
20. Kondo C, Suzuki H, Itoda M et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004 21 : 1895 903
21. Sparreboom A, Gelderblom H, Marsh S et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin Pharmacol Ther 2004 76 : 38 44
22. Zamboni WC, Ramanathan RK, McLeod HL et al. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 2006 24 : 393 401
23. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 2003 278 : 20645 51
24. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005 65 : 6640 50
25. van Herwaarden AE, Jonker JW, Wagenaar E et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res 2003 63 : 6447 52
26. Gardner ER, Burger H, van Schaik RH et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006 80 : 192 201
27. Robey RW, Honjo Y, Morisaki K et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003 89 : 1971 8
28. Robey RW, Medina-Perez WY, Nishiyama K et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001 7 : 145 52
29. Robey RW, Shukla S, Steadman K et al. Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther 2007 6 : 1877 85
30. Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006 45 : 8940 51
31. Mehta CR, Patel NR. A network algorithm for performing Fisher's Exact Test in r × c contingency tables. J Am Stat Assoc 1983 78 : 427 34
32. Hahn NM, Marsh S, Fisher W et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006 12 : 6094 9
33. Velamakanni S, Janvilisri T, Shahi S, van Veen HW. A functional steroid-binding element in an ATP-binding cassette multidrug transporter. Mol Pharmacol 2008 73 : 12 7